PEPG

PepGen Inc. Q1 2026 Filing Summary

Business Context and Reporting Period

PepGen Inc. (PEPG) is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as an emerging growth company and a smaller reporting company. Its primary focus is the development of PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1). The company discontinued its Duchenne Muscular Dystrophy (DMD) program, PGN-EDO51, in May 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by $12.4 million (41%) compared to Q1 2025, primarily driven by a $12.4 million reduction in R&D expenses.
• R&D Expense Decline: R&D expenses dropped significantly due to the discontinuation of the DMD program (PGN-EDO51) in May 2025, a decrease in manufacturing costs related to campaign timing, and lower personnel-related costs.
• Stock-Based Compensation: Total stock-based compensation expense was $2.9 million, down from $3.4 million in the prior year, though this includes incremental expense from a November 2025 option repricing.
• Liquidity Position: Cash and marketable securities decreased by approximately $13.8 million from the end of 2025, reflecting operating cash burn partially offset by $1.5 million in proceeds from an At-the-Market (ATM) offering.

Guidance, Outlook, and Risks

• Clinical Progress: The Phase 1 FREEDOM study for PGN-EDODM1 is complete. The Phase 2 FREEDOM2 study is ongoing in Canada, the U.K., South Korea, Australia, and New Zealand. The U.S. portion of FREEDOM2 remains on a partial clinical hold by the FDA; the company is working to resolve this.
• Financial Outlook: Management believes current cash resources ($132.3 million) are sufficient to fund operations into the second half of 2027. No revenue is expected until regulatory approval is obtained, which is years away.
• Capital Needs: The company will require substantial additional funding to advance PGN-EDODM1 beyond current trials and to support a potential Phase 3 pivotal trial. Future financing may involve equity offerings, debt, or collaborations.
• Key Risks:
  • Regulatory Holds: The partial clinical hold in the U.S. for FREEDOM2 poses a risk to enrollment timelines and development costs.
  • Safety Signals: Transient kidney biomarker abnormalities were observed in Phase 1 and early Phase 2 cohorts, requiring continued monitoring.
  • Single Product Dependence: The business is entirely dependent on the success of PGN-EDODM1 following the discontinuation of the DMD program.
  • Manufacturing: Reliance on third-party suppliers and single-source vendors for critical materials creates supply chain risks.

Investor Verification Checklist

• FDA Status: Verify the current status of the partial clinical hold on the FREEDOM2 study in the U.S. and the timeline for resolution.
• Safety Data: Review detailed safety data regarding the transient kidney biomarker abnormalities observed in clinical trials to assess potential impact on dosing or approval.
• Burn Rate: Confirm the projected cash runway into the second half of 2027 against actual quarterly cash usage.
• Manufacturing Supply: Assess the stability of third-party manufacturing agreements and the availability of secondary suppliers for drug substance.
• Option Repricing Impact: Review the remaining unrecognized stock-based compensation expense ($24.1 million for options) resulting from the November 2025 repricing and its impact on future quarters.